Segment Reporting - Schedule of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total net revenues	$ 2,736	$ 2,529
Gross margin	1,587	1,491
Research and development expenses	556	563
Depreciation and amortization expense	50	46
Selling, general and administrative expenses	1,999	1,950
Change in fair value of contingent consideration		(42)
Total operating expenses	2,605	2,517
Loss from operations	(1,018)	(1,026)
Water Filtration [Member]
Total net revenues	2,736	2,511
Gross margin	1,587	1,480
Research and development expenses	294	310
Depreciation and amortization expense	50	46
Selling, general and administrative expenses	1,876	1,715
Change in fair value of contingent consideration		(42)
Total operating expenses	2,220	2,029
Loss from operations	(633)	(549)
Pathogen Detection [Member]
Total net revenues		18
Gross margin		11
Research and development expenses	119	52
Depreciation and amortization expense
Selling, general and administrative expenses	101	125
Change in fair value of contingent consideration
Total operating expenses	220	177
Loss from operations	(220)	(166)
Renal Products [Member]
Total net revenues
Gross margin
Research and development expenses	143	201
Depreciation and amortization expense
Selling, general and administrative expenses	22	110
Change in fair value of contingent consideration
Total operating expenses	165	311
Loss from operations	(165)	(311)
Consolidated [Member]
Total net revenues	2,736	2,529
Gross margin	1,587	1,491
Research and development expenses	556	563
Depreciation and amortization expense	50	46
Selling, general and administrative expenses	1,999	1,950
Change in fair value of contingent consideration		(42)
Total operating expenses	2,605	2,517
Loss from operations	$ (1,018)	$ (1,026)